viewImmuPharma PLC

Immupharma PLC - Total Share Capital Notification - Replacement

RNS Number : 6454F
Immupharma PLC
18 November 2020

RNS | eCorporate                                                                                                                                  18 November 2020


ImmuPharma PLC

("ImmuPharma" or the "Company")


Total Share Capital Notification - Replacement


The following replaces the 'Total Share Capital Notification' announcement released on 30 September 2020 at 7.01am (BST) under RNS No 5041A.


In Section 2 below the reference to "Share Options in whole or part" should have stated 25,640,254 not 15,703,942.

The full amended text is shown below.



ImmuPharma PLC (LSE:IMM), (Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company announces that in accordance with its obligations to the Company's Euronext listing and following an application of Article 15 of the Belgian Law of 2 May 2007, the total number of shares with voting rights and the total number of voting rights are set out below:


Situation as at 16 June 2020




1. Information to be provided for on the basis of Article 15, §1, al. 1




Total of share capital (nominal value)


£ 24,628,580




Total number of shares with existing voting rights (= denominator) - one vote per share






2. Additional information to be provided on the basis of Article 15, §1, al. 2


In respect to the announcement on 11 June 2020: "Investment from two specialist US healthcare investors"






Convertible Securities (in whole or in part) into ordinary shares currently outstanding.

The total conversion would result in an equal number of voting rights






Share options (in whole or in part)

The exercise of the options would result in the creation of an equal number of ordinary shares and voting rights.




In respect to the announcements on 30 March 2020: "Subscription to raise £1.5m" and 2 September 2020 "Placing to raise £6.5m"






Warrants over ordinary shares (in whole or in part)

The exercise of the warrants would result in the creation of an equal number of ordinary shares and voting rights






Other outstanding rights to subscribe ordinary shares as detailed in the Annual Report 2019 (Report and consolidated financial Statements for the year ended 31 December 2019)






Share options (in whole  or in part)

The exercise of the options would result in the creation of an equal number of ordinary shares and voting rights







This situation (the denominator) serves as a basis for the notification of major holdings by shareholders.


For further information please contact:


ImmuPharma PLC (www.immupharma.com)

Tim McCarthy, Chairman

+ 44 (0) 207 152 4080

Dimitri Dimitriou, Chief Executive Officer


Lisa Baderoon, Head of Investor Relations

+ 44 (0) 7721 413496



SPARK Advisory Partners Limited (NOMAD)

Neil Baldwin


Stanford Capital Partners (Joint Broker)

Patrick Claridge, John Howes


SI Capital (Joint Broker)

Nick Emerson


+44 (0) 203 368 3550



+44 (0) 203 815 8880



+44 (0) 1483 413500



4Reliance (Euronext Growth Listing Sponsor)

Jean-Charles Snoy


Degroof Petercam (Liquidity Provider)

Erik De Clippel


Backstage Communication

Olivier Duquaine

Gunther De Backer

+32 (0) 2 747 02 60



+32 (0) 2 287 95 34




+32 (0) 477 504 784

+32 (0) 475 903 909









Notes to Editors

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM - Euronext Growth: ALIMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases, metabolic diseases, anti-infectives and cancer. The lead program, Lupuzor™, is a first-in class autophagy immunomodulator which is in Phase III for the treatment of lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action. ImmuPharma and Avion Pharmaceuticals signed on 28 November 2019, an exclusive licence and development agreement and trademark agreement for Lupuzor™ to fund a new international Phase III trial for Lupuzor™ and commercialise in the US.


For additional information about ImmuPharma please visit www.immupharma.co.uk 


ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895.



This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

Quick facts: ImmuPharma PLC

Price: -

Market: AIM
Market Cap: -

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...


Immupharma: The Life Sciences Division's Dr Malik says shares are 'oversold'...

The Life Sciences Division's Dr Navid Malik offers up his thoughts and outlook on ImmuPharma PLC (LON:IMM). Malik examines the company's flagship drug Lupuzor - a treatment for the autoimmune disease Lupus. ImmuPharma recently updated the market on progress within its lupus drug, Lupuzor,...

1 week, 5 days ago

6 min read